Jiangsu Hengrui Pharmaceuticals Receives FDA Form 483 Following Inspection Discrepancies
The U.S. Food and Drug Administration (FDA) has issued a Form 483 to Jiangsu Hengrui...
The U.S. Food and Drug Administration (FDA) has issued a Form 483 to Jiangsu Hengrui...
Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, announced that it has...
Carbogen Amcis, a Swiss firm specializing in active pharmaceutical ingredients (APIs) and pharmaceutical process development,...
The U.S. Food and Drug Administration (FDA) has issued a warning letter to Sichuan Deebio...
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
The National Medical Products Administration (NMPA) of China is currently soliciting public feedback on the...
India-based Aurobindo Pharma reportedly received EU GMP approval for its China-based manufacturing plant last week,...
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Henlius Biotech,...
Suzhou-based gene therapy specialist, Gritgen Therapeutics Co., Ltd, has announced the validation completion and initiation...
Singapore-based SCG Cell Therapy Pte. Ltd has announced the initiation of its global manufacturing and...
Brazil-based biotechnology company Biomm (BVMF: BIOM3) has announced that it has in-licensed the late-stage biosimilar...
US-based Mustang Bio, Inc. has announced a strategic partnership with uBriGene (Boston) Biosciences Inc., the...
Shanghai-headquartered Full-Life Technologies Ltd has announced a significant land acquisition deal in the Wallonie region...
The National Health Commission, Ministry of Education, Ministry of Science and Technology, and National Administration...
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) plans to raise RMB 1.56 billion (USD...
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for...
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced receiving...
China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Provisions on the...
Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following...
Biosyngen has announced plans to establish a Cell Therapy GMP Facility in Singapore, aimed at...